Moderna (MRNA) Q3 2025 Earnings Call Transcript

Motley Fool Transcribing, The Motley Fool

Thu, December 11, 2025 astatine 11:44 AM CST 41 min read

Image source: The Motley Fool.

Thursday, November 6, 2025 astatine 8:00 a.m. ET

• Chief Executive Officer — Stéphane Bancel

• President — Stephen Hoge

• Chief Financial Officer — James Mock

Stéphane Bancel: In the 3rd quarter, our gross were $1 billion, driven by income of our afloat approved vaccines, Spikevax, mNEXSPIKE, mRESVIA. The nett nonaccomplishment for the 4th was $200 million. We ended the 4th with $6.6 cardinal successful currency and investments. We stay highly focused connected fiscal discipline. I'm pleased to denote that continued outgo simplification efforts crossed the institution successful the 3rd 4th of 2025 led to a 34% simplification of outgo of sales, R&D and SG&A combined compared to the 3rd 4th of 2024.

Stéphane Bancel: During the quarter, we made bully advancement crossed our 3 strategical priorities. Our archetypal precedence is driving usage of our commercialized products. For Spikevax, our archetypal COVID vaccine, we received support successful 40 countries for the seasonal 2025-2026 strain update. And mNEXSPIKE, our caller COVID vaccine was approved this twelvemonth by the FDA. We besides filed and received support for the 2025-2026 strain update successful the U.S. making this the archetypal play that mNEXSPIKE is disposable successful the United States. We besides received support for mNEXSPIKE successful Canada. For RSV vaccine, mRESVIA, volition proceed to summation regulatory support and mRESVIA is present approved successful 40 countries.

We person a strategical concern with 3 countries, Canada, the U.K. and Australia, wherever we person established manufacturing facilities and secured a multiyear offtake agreements. In each of these countries, we person achieved important milestones. In Canada, we delivered the archetypal made-in-Canada mRNA vaccines to the Canadian authorities for usage this season. In the U.K. and Australia, our facilities were granted licenses by their respective regulatory agencies.

Stéphane Bancel: Second priority, advancing our pipeline to drawback income growth. We announced successful July, affirmative Phase III flu efficacy information which we judge volition beforehand some our flu vaccine program, mRNA-1010 and our flu positive COVID operation program, mRNA-1083. For the flu positive COVID operation program, our filing continues to beryllium nether reappraisal by the European Medicines Agency. In Oncology portfolio astatine the European Society of Medical Oncology, ESMO, Congress successful October, we presented encouraging Phase Ib information for crab antigen therapy, mRNA-4359. Unfortunately, we besides announced precocious that contempt the advancement made by the technological assemblage successful knowing the CMV virus, our CMV programme did not conscionable its superior efficacy endpoints for congenital CMV.